NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 as Measles Treatment
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral developer, announced that it has filed an application with the U.S. Food and Drug Administration Office of Orphan Products Development for Orphan Drug Designation for NV-387 as a treatment for measles. If granted, the designation would make the Company eligible for incentives including tax credits for qualified clinical trials, exemptions from certain FDA user fees, and up to seven years of market exclusivity following approval, supporting the regulatory development of NV-387 amid rising measles cases in the United States and globally. To view the full press release, visit https://nnw.fm/EoqGv ABOUT NANOVIRICIDES NanoViricides, Inc. (the…







